皮膚科治療薬市場- 世界の産業規模、シェア、動向、機会、予測、治療法別、タイプ別、投与経路別、薬剤クラス別、流通チャネル別、地域別、競合別、2020-2030F

皮膚科治療薬の世界市場規模は2024年に217億5,000万米ドルとなり、2030年までのCAGRは9.05%で、予測期間中に目覚ましい成長を遂げると予測されています。

皮膚科治療薬は、様々な皮膚疾患や障害の治療と管理のために特別に設計された医薬品です。皮膚科学は、皮膚、毛髪、爪、粘膜に影響を及ぼす疾患や状態の診断、治療、予防に焦点を当てた医学の専門分野です。皮膚科治療薬は、一般的な皮膚疾患からより複雑な疾患まで、幅広い皮膚科学的問題に対処する上で重要な役割を果たします。これらの皮膚科治療薬は、注射や点滴として投与されることが多い、新しいタイプの皮膚科治療薬です。乾癬、湿疹、尋常性天疱瘡などの自己免疫性皮膚疾患に用いられます。生物学的製剤は特定の免疫系成分を標的として炎症を抑え、症状を管理します。皮膚疾患の中には、全身に作用する治療が必要なものもあります。これらの薬剤には、コルチコステロイド、免疫抑制剤、標的療法などがあります。

にきび、乾癬、湿疹、皮膚がん、皮膚炎など、様々な皮膚疾患の高い有病率が皮膚科治療薬の需要を牽引しています。皮膚疾患は世界人口のかなりの部分に影響を及ぼしており、安定した市場需要につながっています。世界の高齢化社会では、皮膚がんや加齢に伴う皮膚症状など、皮膚科学的な問題が発生しやすくなっています。高齢者人口の増加に伴い、加齢に伴う症状に対する皮膚科治療薬の需要も増加しています。継続的な研究開発努力の結果、皮膚疾患に対する革新的な治療法や薬剤が発見されています。生物製剤、標的治療薬、新規製剤の進歩が市場の成長に寄与しています。しわの減少や肌の若返りといった美容皮膚科や美容治療への関心の高まりは、化粧品・美容業界における皮膚科治療薬や施術の需要を押し上げています。汚染や気候変動などの環境要因は、皮膚の問題を引き起こす可能性があります。このような環境への懸念は、汚染に関連した皮膚問題に対処する皮膚科治療薬の需要を促進する可能性があります。

主要市場促進要因

皮膚疾患の有病率の上昇

主な市場課題

抵抗性と耐性

主要市場動向

個別化医療

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 皮膚科治療薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 治療法別（ニキビ、乾癬、酒さ、脱毛症、その他）
  • タイプ別（処方薬、市販薬）
  • 投与経路別（局所、経口、非経口）
  • 薬剤クラス別（コルチコステロイド、レチノイド、抗生物質、抗真菌剤、カルシニューリン阻害剤、その他）
  • 流通チャネル別（病院薬局、小売薬局、その他）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 北米の皮膚科治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の皮膚科治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋地域の皮膚科治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米の皮膚科治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの皮膚科治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界の皮膚科治療薬市場：SWOT分析

第14章 競合情勢

• AbbVie Inc.
• Pfizer Inc.
• Glaxo Smith Kline PLC
• Sun Pharmaceutical Industries Ltd
• Galderma SA
• Amgen Inc
• Johnson & Johnson Services, Inc.
• Novartis AG
• Almirall, S.A
• Eli Lilly and Company
• Bausch Health Companies Inc.

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Dermatological Drugs Market was valued at USD 21.75 Billion in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 9.05% through 2030. Dermatological drugs are medications specifically designed for the treatment and management of various skin conditions and disorders. Dermatology is a medical specialty that focuses on the diagnosis, treatment, and prevention of diseases and conditions affecting the skin, hair, nails, and mucous membranes. Dermatological drugs play a crucial role in addressing a wide range of dermatological issues, from common skin conditions to more complex disorders. These are a newer class of dermatological drugs that are often administered as injections or infusions. They are used for autoimmune skin diseases like psoriasis, eczema, and pemphigus vulgaris. Biologics target specific immune system components to reduce inflammation and manage symptoms. Some dermatological conditions require systemic treatments that affect the entire body. These medications can include corticosteroids, immunosuppressive drugs, and targeted therapies.

The high prevalence of various skin conditions, including acne, psoriasis, eczema, skin cancer, and dermatitis, drives the demand for dermatological drugs. Skin conditions affect a significant portion of the global population, leading to a consistent market demand. The global aging population is more prone to dermatological issues, including skin cancers and age-related skin conditions. As the elderly population increases, the demand for dermatological drugs for conditions associated with aging also rises. Ongoing research and development efforts result in the discovery of innovative treatments and drugs for dermatological conditions. Advancements in biologics, targeted therapies, and novel formulations contribute to market growth. The growing interest in cosmetic dermatology and aesthetic treatments, such as wrinkle reduction and skin rejuvenation, boosts the demand for dermatological drugs and procedures in the cosmetic and beauty industry. Environmental factors, such as pollution and climate change, can lead to skin issues. These environmental concerns can drive the demand for dermatological drugs that address pollution-related skin problems.

Key Market Drivers

Rising Prevalence of Skin Diseases

The rising prevalence of skin diseases is one of the most significant drivers propelling the growth of the global dermatological drugs market. As skin disorders become more widespread due to environmental, genetic, and lifestyle-related factors, the demand for effective pharmaceutical treatments continues to surge. This trend creates substantial opportunities for pharmaceutical companies, biotechnology firms, and healthcare providers. Skin diseases are among the most common health conditions worldwide, affecting millions of individuals across different demographics. Skin diseases represent the most prevalent category of human illnesses, impacting approximately 900 million individuals worldwide at any given time. According to the Global Burden of Disease Project, dermatological conditions rank as the fourth leading contributor to the global non-fatal disease burden, underscoring their significant impact on healthcare systems, workforce productivity, and pharmaceutical demand. The Global Burden of Disease (GBD) study ranks skin disorders among the top 10 causes of non-fatal disability worldwide. Chronic dermatological conditions such as psoriasis, eczema, acne, rosacea, vitiligo, and skin infections require long-term management, increasing the demand for prescription and over-the-counter (OTC) dermatological drugs. As a result, pharmaceutical companies are focusing on expanding their product portfolios, leading to market growth through increased drug production and sales.

Key Market Challenges

Resistance and Tolerance

Resistance to topical antibiotics can develop in the treatment of conditions like acne and impetigo. Prolonged use of antibiotics may lead to the development of antibiotic-resistant strains of bacteria on the skin. Resistance to antifungal drugs can occur in the treatment of fungal skin infections, such as dermatophytosis (ringworm) and candidiasis. Fungi can develop resistance to commonly used antifungal agents. Prolonged use of topical corticosteroids can lead to skin thinning and tolerance, where the drug becomes less effective in managing inflammatory skin conditions like eczema and psoriasis. In some cases, acne-causing bacteria can become resistant to antibiotics commonly used in acne treatment. This has led to the development of alternative treatments and the importance of antibiotic stewardship. Some individuals may develop tolerance to OTC products like benzoyl peroxide or salicylic acid when used for acne for acne. This may necessitate a change in treatment or the addition of other therapies. In conditions like psoriasis, the immune system can become resistant to certain treatments, such as topical corticosteroids or phototherapy. This may require the use of different classes of drugs or combination therapies. Dermatologists often use combination therapies that target multiple aspects of a skin condition to reduce the risk of resistance or tolerance. This approach can include combining topical medications, systemic treatments, and non-pharmacological interventions.

Key Market Trends

Personalized Medicine

Individuals can respond differently to dermatological treatments due to genetic variations. Personalized medicine seeks to identify these genetic factors to predict treatment responses and outcomes accurately. Pharmacogenomics is the study of how an individual's genetic makeup influences their response to medications. In dermatology, this is particularly relevant for drugs used to treat conditions like psoriasis and acne. Personalized medicine is crucial in the treatment of skin cancers, such as melanoma. Genetic profiling of tumors can guide treatment decisions, including the use of targeted therapies and immunotherapies. Genetic factors play a role in atopic dermatitis (eczema). Personalized medicine can help identify specific genetic markers that influence disease severity and treatment response, allowing for tailored interventions. Genetic testing and molecular diagnostics can help dermatologists select the most appropriate treatment for specific skin conditions, ensuring better outcomes and minimizing side effects. Some companies have developed customized topical treatments based on individual skin characteristics and needs. These formulations are designed to address specific skin concerns, such as acne or hyperpigmentation. Personalized medicine can identify genetic risk factors for skin conditions like skin cancer. Patients with a higher genetic risk may receive more frequent screenings and preventive interventions. By tailoring treatments based on an individual's genetic profile, dermatologists can minimize the risk of adverse effects and optimize treatment safety and efficacy.

Key Market Players

• AbbVie Inc.
• Pfizer Inc.
• Glaxo Smith Kline PLC
• Sun Pharmaceutical Industries Ltd
• Galderma SA
• Amgen Inc
• Johnson & Johnson Services, Inc.
• Novartis AG
• Almirall, S.A
• Eli Lilly and Company
• Bausch Health Companies Inc.

Report Scope:

In this report, the Global Dermatological Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Dermatological Drugs Market, By Therapy Type:

• Acne
• Psoriasis
• Rosacea
• Alopecia
• Others

Dermatological Drugs Market, By Type:

• Prescription
• Over-the-counter

Dermatological Drugs Market, By Route of Administration:

• Topical
• Oral
• Parenteral

Dermatological Drugs Market, By Drug Class:

• Corticosteroids
• Retinoids
• Antibiotics
• Antifungals
• Calcineurin Inhibitors
• Others

Dermatological Drugs Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Others

Dermatological Drugs Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Dermatological Drugs Market.

Available Customizations:

Global Dermatological Drugs Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Dermatological Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapy (Acne, Psoriasis, Rosacea, Alopecia, Others)
  • 5.2.2. By Type (Prescription, Over-the-counter)
  • 5.2.3. By Route of Administration (Topical, Oral, Parenteral)
  • 5.2.4. By Drug Class (Corticosteroids, Retinoids, Antibiotics, Antifungals, Calcineurin Inhibitors, Others)
  • 5.2.5. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others)
  • 5.2.6. By Region
  • 5.2.7. By Company (2024)
• 5.3. Market Map

6. North America Dermatological Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapy
  • 6.2.2. By Type
  • 6.2.3. By Route of Administration
  • 6.2.4. By Drug Class
  • 6.2.5. By Distribution Channel
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Dermatological Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapy
      • 6.3.1.2.2. By Type
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By Drug Class
      • 6.3.1.2.5. By Distribution Channel
  • 6.3.2. Canada Dermatological Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapy
      • 6.3.2.2.2. By Type
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By Drug Class
      • 6.3.2.2.5. By Distribution Channel
  • 6.3.3. Mexico Dermatological Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapy
      • 6.3.3.2.2. By Type
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By Drug Class
      • 6.3.3.2.5. By Distribution Channel

7. Europe Dermatological Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapy
  • 7.2.2. By Type
  • 7.2.3. By Route of Administration
  • 7.2.4. By Drug Class
  • 7.2.5. By Distribution Channel
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Dermatological Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapy
      • 7.3.1.2.2. By Type
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By Drug Class
      • 7.3.1.2.5. By Distribution Channel
  • 7.3.2. United Kingdom Dermatological Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapy
      • 7.3.2.2.2. By Type
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By Drug Class
      • 7.3.2.2.5. By Distribution Channel
  • 7.3.3. Italy Dermatological Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Therapy
      • 7.3.3.2.2. By Type
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By Drug Class
      • 7.3.3.2.5. By Distribution Channel
  • 7.3.4. France Dermatological Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Therapy
      • 7.3.4.2.2. By Type
      • 7.3.4.2.3. By Route of Administration
      • 7.3.4.2.4. By Drug Class
      • 7.3.4.2.5. By Distribution Channel
  • 7.3.5. Spain Dermatological Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Therapy
      • 7.3.5.2.2. By Type
      • 7.3.5.2.3. By Route of Administration
      • 7.3.5.2.4. By Drug Class
      • 7.3.5.2.5. By Distribution Channel

8. Asia-Pacific Dermatological Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapy
  • 8.2.2. By Type
  • 8.2.3. By Route of Administration
  • 8.2.4. By Drug Class
  • 8.2.5. By Distribution Channel
  • 8.2.6. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Dermatological Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapy
      • 8.3.1.2.2. By Type
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By Drug Class
      • 8.3.1.2.5. By Distribution Channel
  • 8.3.2. India Dermatological Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapy
      • 8.3.2.2.2. By Type
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By Drug Class
      • 8.3.2.2.5. By Distribution Channel
  • 8.3.3. Japan Dermatological Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapy
      • 8.3.3.2.2. By Type
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By Drug Class
      • 8.3.3.2.5. By Distribution Channel
  • 8.3.4. South Korea Dermatological Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Therapy
      • 8.3.4.2.2. By Type
      • 8.3.4.2.3. By Route of Administration
      • 8.3.4.2.4. By Drug Class
      • 8.3.4.2.5. By Distribution Channel
  • 8.3.5. Australia Dermatological Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Therapy
      • 8.3.5.2.2. By Type
      • 8.3.5.2.3. By Route of Administration
      • 8.3.5.2.4. By Drug Class
      • 8.3.5.2.5. By Distribution Channel

9. South America Dermatological Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapy
  • 9.2.2. By Type
  • 9.2.3. By Route of Administration
  • 9.2.4. By Drug Class
  • 9.2.5. By Distribution Channel
  • 9.2.6. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Dermatological Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapy
      • 9.3.1.2.2. By Type
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By Drug Class
      • 9.3.1.2.5. By Distribution Channel
  • 9.3.2. Argentina Dermatological Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapy
      • 9.3.2.2.2. By Type
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By Drug Class
      • 9.3.2.2.5. By Distribution Channel
  • 9.3.3. Colombia Dermatological Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapy
      • 9.3.3.2.2. By Type
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By Drug Class
      • 9.3.3.2.5. By Distribution Channel

10. Middle East and Africa Dermatological Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Therapy
  • 10.2.2. By Type
  • 10.2.3. By Route of Administration
  • 10.2.4. By Drug Class
  • 10.2.5. By Distribution Channel
  • 10.2.6. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Dermatological Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Therapy
      • 10.3.1.2.2. By Type
      • 10.3.1.2.3. By Route of Administration
      • 10.3.1.2.4. By Drug Class
      • 10.3.1.2.5. By Distribution Channel
  • 10.3.2. Saudi Arabia Dermatological Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Therapy
      • 10.3.2.2.2. By Type
      • 10.3.2.2.3. By Route of Administration
      • 10.3.2.2.4. By Drug Class
      • 10.3.2.2.5. By Distribution Channel
  • 10.3.3. UAE Dermatological Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Therapy
      • 10.3.3.2.2. By Type
      • 10.3.3.2.3. By Route of Administration
      • 10.3.3.2.4. By Drug Class
      • 10.3.3.2.5. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Dermatological Drugs Market: SWOT Analysis

14. Competitive Landscape

• 14.1. AbbVie Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. Pfizer Inc.
• 14.3. Glaxo Smith Kline PLC
• 14.4. Sun Pharmaceutical Industries Ltd
• 14.5. Galderma SA
• 14.6. Amgen Inc
• 14.7. Johnson & Johnson Services, Inc.
• 14.8. Novartis AG
• 14.9. Almirall, S.A
• 14.10.Eli Lilly and Company
• 14.11.Bausch Health Companies Inc.

15. Strategic Recommendations

16. About Us & Disclaimer